Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 in hormone refractory prostate cancer
NCT00257478Phase 2Completed
- Sponsor
- Astellas Pharma
- Modality
- Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of sepantronium in prostate cancer (PCa), sponsored by Astellas Pharma. Status: completed.
02
Drugs
sepantronium
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00257478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257478.